

INDEX

ADDICTION

central nervous system, 340
 conditioning of smoking habit, 78–79, 340, 342
 development of smoking habit, 333–334
 health warnings, recommendations, 486
 historical perspective, 329–330, 340–342
 National Institute on Drug Abuse, research programs, 399
 nicotine, psychosocial and pharmacologic forces, 331, 334, 340, 342
 public beliefs about tobacco use, 200, 216
 relationship to price elasticity, 537
 withdrawal symptoms, 343–344

ADOLESCENTS

access to tobacco, 235, 238, 596–604, 606
 advertising effects, 339, 503–504, 660
 behavioral risk factors compared with smoking, beliefs, 215
 beliefs about smoking, 212–215, 216, 222–223
 cessation attempts, British and American teenagers, 596
 cigarette consumption, 660
 developmental stage models, peer pressure and coping patterns, 386
 drug and alcohol use vs. smoking, beliefs, 214, 215
 free tobacco product samples, 597
 High School Seniors Surveys, 302–303, 306
 initiation of smoking, 215, 296–297, 333–335, 537–539
 knowledge about smoking and smokeless tobacco use, 217, 221, 222–223
 parental and peer influences, 336–338, 389, 390
 perceptions about smokers their own age, 227–229
 prevention of smoking, programs, 394–396, 398, 407–408
 price elasticity of demand for cigarettes, 536–539
 psychosocial curricula, 385, 389, 390

smokeless tobacco and oral neoplasm risk, 217, 218
 smoking cessation programs, 392–393
 social trends and smoking prevalence, 409
 Surgeon General's Reports, smoking prevention, 400–401

ADULT USE OF TOBACCO SURVEYS (AUTSs)

airplane smoking restrictions, 573
 employee smoke exposure after restriction implementation, 594
 cigar and pipe smoking, 322, 326–328
 methodology and scope, 246–247
 public service announcements, 497
 smokeless tobacco use, 319–321
 smoking continuum of quitting process, 286, 288–289, 292
 smoking prevalence, 266, 271–272
 tar yields of cigarettes, 315
 tobacco use, 359
 workplace smoking policies, prevalence, 582

ADVERTISING

(*See also* **PROMOTION**)

broadcast bans, 511, 514, 660–661
 Cigarette Advertising Code, 511
 consumption effects, 501–503, 514, 660–661
 decreased motivation to stop smoking, 502
 disincentives, 516
 expenditures, 499–500, 503, 507, 514, 661
 Fairness Doctrine, application to cigarettes, 414–415
 Federal Trade Commission action against R.J. Reynolds, 512
 Federal Trade Commission guidelines for evaluation, 510–511
 guidelines, cigarette smoke constituents, 488–490
 health warnings, 476, 479, 483–484
 imagery and content regulation, proposals, 515

- initiation of smoking, 501
- legibility of advertisements, 483–484
- low-tar and -nicotine cigarettes, 665
- market maturity and segmentation, strategy, 506
- preemption of State and local restrictions, 512
- public health impact, 501
- public transit bans, 513, 514–515
- recall by children, effect on smoking behavior, 505–506
- recidivism, 502
- regulation of health claims by cigarette manufacturers, 510
- restrictions or prohibition, 178, 239–240, 515–516
- revenues, media coverage, 508–510
- stadium ban, Minneapolis, 513
- teenager targets, 338–339, 503–504
- tobacco industry questions about harmfulness of smoking, 511–512

ADVOCACY

- American Lung Association, 417, 442
- attempts to shift public perceptions, 436–437
- Coalition on Smoking OR Health, 439, 440, 443
- Comprehensive Smoking Education Act of 1984, 437
- educational and behavioral programs, policy initiatives, 383
- Fairness Doctrine, antismoking lobbying, 441–442
- National Commission on Smoking and Public Policy, 443
- National Interagency Council on Smoking and Health, 437–438
- nonsmokers' rights movement, 415, 442–443, 558
- objectives, 437–439
- organizational characteristics of smoking control groups, 432–440
- State and local antismoking lobbying, 444
- Tobacco-Free America Project, 383

AGE FACTORS

- adult smokers and ex-smokers at risk, 134–137
- Alameda County Study, mortality, 41
- antismoking campaign effects among birth cohorts, 651–657
- cigar and pipe smoking, 327–328
- coronary mortality, sex ratio, 144–145
- initiation of smoking, 296–300, 537–539
- lung cancer mortality, sex ratio, 143–144

- mortality postponed or avoided, 667, 668, 669
- smokeless tobacco use, males, 322–324
- smoking continuum, 289, 291, 292
- statistical analysis and relative risk, women, 127
- tar yields or menthol cigarettes, 316

ANTISMOKING CAMPAIGNS

- American Cancer Society, 414
- American College of Chest Physicians, 419–420
- American Heart Association, 414
- American Medical Association, 418–420
- Coalition on Smoking OR Health, 418
- Department of Defense, 425–427, 575
- Doctors Ought to Care, 419
- Fairness Doctrine, application to cigarette advertising, 414–415
- Federal Government efforts, 396–401, 649–657
- funding sources, 516
- Great American Smokeout day, 416–417, 426
- Health Objectives for the Nation, 16–19, 433
- health professional associations, 418–420
- mass-media-based programs, 384–385
- mortality postponed or avoided, 666–669
- National Cancer Institute, 398–399, 421–423
- National Heart, Lung, and Blood Institute, 399, 423–425
- National Institute for Child Health and Human Development, 399–400
- National Interagency Council on Smoking and Health, 395–396, 437–438
- national voluntary health organizations, 394–395, 417–418
- nationwide, net health consequences, 665–669
- nonsmokers' rights movement, 442–443
- Office of Disease Prevention and Health Promotion, 425
- Office on Smoking and Health, 397–398, 421
- organizational characteristics of advocacy groups, 439–440
- State health departments, 427
- Surgeon General's Reports, 400–401

ANTISMOKING MATERIALS

- American Academy of Family Physicians, 420
- American Cancer Society, 395
- American Heart Association, 394–395

American Lung Association, 394, 414
American Society of Internal Medicine, 420
National Cancer Institute programs, 421–423

ARTERIOSCLEROSIS

aortic and coronary atherosclerosis, 60–61
claudication and aortic aneurysm mortality, 65–66
peripheral vascular disease claudication, 63, 65

Asian Americans/Pacific Islanders

See **ETHNIC GROUPS**

ATTITUDES

(See also **ADULT USE OF TOBACCO SURVEYS; CANCER PREVENTION STUDIES; NATIONAL HEALTH INTERVIEW SURVEYS; SMOKING SURVEYS**)

addictive nature of tobacco use, 200, 202
adolescents, 212–215, 216, 217–218, 227–229, 409
air pollution, health risks, 207, 209–210, 211
alcohol consumption, health risks, 207–212
asbestos exposure and smoking, lung neoplasm risk, 202
ban on free samples, 239
blacks, risk factors for cardiovascular diseases, 212
bladder neoplasms, smoking relationship, 195
broadcast antismoking messages, impact on public opinion, 415
carbon monoxide in tobacco smoke, 217
cessation of smoking, health effects, 219, 220
children, harmfulness of smoking, *Weekly Reader* survey, 215–216
chronic obstructive pulmonary disease, smoking relationship, 188, 193–194, 195
consumption of cigarettes, health risks, 184
coronary heart disease, smoking relationship, 188, 191–192
duration of smoking, health risks, 185, 186–187
smoking-and-health reports, effects on public knowledge, 519
esophageal neoplasms, smoking relationship, 195, 196

health effects of smoking, 179–181, 219, 221–222
heavy vs. light smoking, 181–184, 221
hiring of smokers, 241
inflight smoking bans, 573, 574
involuntary smoking, 200, 201, 224, 225
laryngeal neoplasms, smoking relationship, 195, 196
life expectancy, risks of smoking, 206
low-yield cigarettes, health risks, 183, 185, 221
lung neoplasms, smoking relationship, 185, 186, 188, 189–190
neoplasms, smoking as risk factor, 212
nonsmokers rights, 224, 226
obesity, health risks, 207–212
oral contraceptives, interactions and risks, 197–199
peer influence on smoking, 336–338
pregnancy, dangers of smoking, 197
restrictions on smoking in public, 230–239, 578
risk models, 206–212
smokeless tobacco use, mouth and throat neoplasms, 202
smokers, personal risk, 202–204, 205
smoking-and-health advocacy groups, attempts to change public perceptions, 436–437
survey methodology, 176–178
tobacco access laws, law enforcement officials, 605–606
types of cigarettes, harmfulness, 181
women, dangers of smoking, 195, 197–199
workplace restrictions, 578, 589, 600–601

BEHAVIOR, HUMAN

actions of smokers among nonsmokers, 227
child risk taking, 399–400
estimated risks of various activities, 160
health risk knowledge vs. smoking habit, 344–345
self-efficacy and smoking cessation, 351
self-reported smoking status, 265–266
switching cigarette types, antismoking campaign, 664–665

BIOASSAY

biochemical markers, mainstream and sidestream smoke, 94–97
smoking status validation, vs. self reports, 265
thiocyanates and diet, 96

BIRTH DEFECTS

- parental smoking, 73, 75
- cessation of smoking, 73
- fetal hypoxia and carbon monoxide, 72
- maternal smoking, dose-response effect, 72

BLACK AMERICANS

- adolescents, smoking prevalence, 303–306
- cardiovascular disease risk, beliefs, 212
- initiation of smoking, 301–302
- maternal smoking, 72, 73–74, 275
- prevalence of smoking, 269–271
- quit ratios, gender, 286
- self-reported daily cigarette consumption, heavy smokers, 295
- statistical bias, lung cancer risk among women, 129
- tar and nicotine content, beliefs about health risks, 183, 185

CALIFORNIA

- nonsmokers' rights group, proposition on 'smoking restrictions, 442
- public transit bans, 513, 574
- restaurant smoking restrictions, Beverly Hills, 571
- Safe Drinking Water and Toxic Substances Enforcement Act, 612
- San Diego study, National Clearinghouse for Smoking and Health, 397
- warning labels, tobacco products, 612
- workplace smoking restrictions, 570–571, 577

CANADA

- ban on tobacco advertising and promotion, 516
- public beliefs about addictive nature of tobacco use, 200, 202
- Tobacco Products Control Act, 487
- transportation smoking restrictions, 574, 588–589

CANCER PREVENTION STUDIES (AMERICAN CANCER SOCIETY)

- chronic obstructive pulmonary disease and smoker mortality, 146
- comparability with other studies, 140–141
- coronary heart disease and smoker mortality, 144–145
- estimated relative risks, cancer, coronary and pulmonary diseases, 146–152
- lung cancer and smoker mortality, 143–144

- mortality, 122, 142
- relative risk changes, 131–132
- sampling bias and validity, 128–129

CARBON MONOXIDE

- advertising guidelines, 488–489
- carboxyhemoglobin, biochemical markers, 96
- public beliefs about tobacco smoke constituents, 217

CARCINOGENESIS

- adenomas, adenocarcinomas, and carcinomas, long-term smoke exposure, 93
- polynuclear aromatic hydrocarbons and N-heterocyclic hydrocarbons, 85
- tumorigenic agents in tobacco, 86–87
- reduction by tobacco additives, 614

CEREBROVASCULAR DISORDERS

- drug therapy efficacy, 63
- estimated relative risks, 1960s and 1980s, 147–152
- Japanese-American men, Hawaii, 62
- mortality and morbidity, 61–62
- public beliefs about smoking and oral contraceptive use, 197, 198
- risk factors, 61–62, 63
- women and smoking habit, 62–63

CESSATION OF SMOKING

- adolescent attempts, Britain and United States, 596
- advertising and promotion of tobacco, effects, 502
- brand-switching as alternative, health consequences, 665–666
- cardiovascular disease risk reduction, 423–424
- cerebrovascular disease risk reduction, 147, 152
- ethnic and demographic differences, 286–287
- expectancy-value and health-belief decisionmaking models, 350–351
- gender differences, 354
- historical perspectives, 330, 434–436
- hospital restrictions, impact, 589, 592
- immediate vs. long-term effects of tobacco, 393
- indicators of quitting activity, 285
- insurance, 551–552, 552–553
- lung cancer risk reduction, 55, 127
- nicotine dependence, 349
- outcome expectations, 352

- pharmacologic processes and conditioning, 349
- physician impact, 418–420
- precontemplation, contemplation, and action stages, 348
- pregnant women, 353, 400
- public beliefs about health effects, 219, 220
- reimbursement of drug treatment, 553
- restrictions as incentive, 578–579
- role of disease incidence, 352–353
- self-efficacy model, 351–352
- smoking continuum of quitting process, 288–289, 292
- stage model, opportunities for older adolescents, 386
- stages, 413
- trends, 287
- workplace policies, 354–355, 589, 563
- workplace restrictions, impact, 592
- young smokers, quit attempts, 392

CESSATION OF SMOKING, METHODS

- acupuncture, 431
- American Lung Association materials, 414
- clonidine, 428
- commercial programs, 427, 431–432
- computer-assisted program, 431
- filter systems, 430
- Great American Smokeout day, 416–417
- history of aids and treatments, 409–413
- How to Quit Smoking workplace program, 432
- how-to-quit materials, 430
- hypnosis, 431
- interpersonal support, 354–355
- Live for Life workplace program, 432–433
- lobeline sulfate capsules, 428
- nicotine polacrilex gum, 428–429, 553, 616
- nonpharmacologic aids, 430–431
- pharmacist's antismoking materials, 425
- pharmacologic cessation aids, 428–429
- physician advice and materials, 418–419, 422–423
- quit rates for different treatments, 410–413
- Schick Stop Smoking program, 432
- silver acetate, 428
- Smoke Stoppers program, 433
- smokeless cigarettes, 430
- Smokeless program, 433
- SmokEnders program, 431

CHILDREN

- access to tobacco, 596–597, 599–603, 603–604
- beliefs about harmfulness of smoking, *Weekly Reader* survey, 215–216
- intervention approaches for young smokers, 386
- maternal smoking, long-term effects, neurological handicaps, 75–76
- parental smoking effects, 336–338
- penalties for tobacco possession, 603
- psychosocial approaches to antismoking education, 385
- recall of cigarette advertisements, effect on smoking behavior, 505–506
- revenue from tobacco sales to minors, 605
- States prohibiting free tobacco samples for minors, 599–602
- Surgeon General's Reports, smoking prevention, 400–401

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

- age-specific death rates, 146
- attributable risks, sex ratio, 153–161
- morbidity and mortality, 66–67, 71, 141–142
- pathogenesis, enzyme activity, 67
- pathophysiology, emphysema and small-airway injury, 67–68
- public beliefs about smoking relationship, 188, 193–194, 195
- respiratory function tests, 68–70
- ventilatory function, 68–71

CIGAR SMOKING

- age-adjusted relative risks, 153
- gender, age, race, socioeconomic and demographic factors, 322, 326–328
- lung cancer mortality, 50
- mortality, vs. pipes vs. cigarettes, 41–42
- prevalence rates, men, 134

CIGARETTES, LOW-NICOTINE

- alternative to cessation, antismoking campaign, 664–665
- lung cancer mortality, 44, 46
- public beliefs about health risks, 183, 185
- yield, sales, consumption, 313–314

CIGARETTES, LOW-TAR

- alternative to cessation, antismoking campaign, 664–665
- changes in tobacco products, risk assessment, 139
- lung cancer mortality, 44, 46

public beliefs about health risks, 183, 185, 221
safety and public perceptions, 416
yield, sales, consumption, 313–315

CIGARETTES, LOW-YIELD

alternative to cessation, antismoking campaign, 664–665
consumption, 658
health effects, 315–316, 666
market share, 665
public health concerns, 183, 185, 490
safety and public perceptions, 416
tar and nicotine reductions in filtered products, 85, 88

COGNITION

developmental model of smoking acquisition and prevention, 391–392
health effects of smoking, knowledge, 335–336, 344–345
Health Objectives for the Nation, 1990, public knowledge, 223–224
health warnings, effectiveness of wording and format, 484
risk assessment, understanding by public, 222
smoking cessation, 348–349, 350–351, 351–352, 353

COLORADO

Aspen, smoking ordinances, effects on business, 572

CONDITIONING

biological effects of nicotine, 343
environmental smoking cues, 349–350
pharmacologic effects of nicotine in smoking cessation, 349
withdrawal symptom relief, 343–344

CORONARY HEART DISEASE

age-specific death rates, 144–145
attributable risks, 153–161
avoidable risk from smoking, 131
Cancer Prevention Studies, risk factors and potential bias, 128
changes in risk behavior, with smoking, 139–140
diabetes as risk factor, 59
estimated relative risks, 147–151
myocardial infarct risk, mortality and treatment, 58–59, 61
nonsmoker mortality, 141–142
pathophysiologic mechanisms, 60–61
public beliefs about smoking relationship, 188, 191–192

risk factors and smoking, 59–60
smoking cessation effects, 61
survey of patients' siblings on risk factors, smoking, 212

DEMOGRAPHIC FACTORS

bias in risk assessments, 128
cigar and pipe smoking, 327–328
education, 269, 271, 286, 287, 289–290, 292, 301–302, 303–306, 316
gender, 276, 322–326
gender, socioeconomic, and personality variables, smoking habit, 329
personal characteristics and smoking, 347
region, gender, education, and smoking prevalence, 279, 282–283
smoking cessation and relapse, 353
variation among antismoking strategies, 408–409

DIET

cholesterol, 207, 209–210, 212
hypercholesterolemia, 139–140
lung cancer and protective effects of vitamins, 54

DRUG ABUSE

adolescent beliefs, smoking vs. other substance use, 214, 215
cigarettes as a "gateway drug," 399
integration of smoking prevention programs into substance abuse programs, 401
marijuana smoking, public beliefs, 207, 211
school health education programs, 388–389

ECONOMICS

ban on cigarette sales, public opinion, 235, 237
cigarette prices in military commissaries, 426
consumer demand and production factors, 660–661
institutional dependence on tobacco industry, effect on consumption, 502
price elasticity, 533–538, 662–664
public service announcements, effects on cigarette consumption, 498
public transit advertising ban, impact, 514–515
restaurant smoking ban, effect on business, Aspen, 572
trends in per capita cigarette consumption, 267–268

Education

See **DEMOGRAPHIC FACTORS;
HEALTH EDUCATION**

EMPHYSEMA

airflow obstruction, 67–68
morbidity and mortality, chronic obstructive lung disease, 66–68
protease–antiprotease activities in pathogenesis, 67
public beliefs about smoking relationship, 188, 193–194, 195

Environmental tobacco smoke

See **INVOLUNTARY SMOKING**

ETHNIC GROUPS

(See also **BLACK AMERICANS)**

Asian Americans, Hawaii, smoking prevalence, 275
cigar and pipe smoking, 327–328
Hispanics, smoking prevalence, 274
Native Americans and Alaskan Natives, smoking prevalence, 274
race and smoking continuum, 289, 291, 292
racial differences in smoking onset and prevalence, 338
smokeless tobacco use, 322–324
tar yields and menthol cigarettes, 316

EX-SMOKERS

age factors, 136
attributable risk, lung cancer, and women, 127
health benefits of smoking cessation, 666, 667
lung cancer risk reduction, 55
measurement of quitting activity, 285
mortality, sex ratio, 147–152
prevalence, 132–134, 288–289
public beliefs about risk reduction after smoking cessation, 219, 220
self-attained cessation of smoking, 413

FILTERS

lung cancer mortality, 44, 46
reduction of toxic and tumorigenic agents in cigarettes, 85
sales, consumption, 313–314
shift from unfiltered, antismoking campaign, 664–665
use, lower yield cigarettes, 138–139

FIRES

fire-safe cigarettes, development and feasibility, 614

insurance, smoking-related deaths and damage, 550
smoking-related deaths, 614

Former smokers

See **EX-SMOKERS**

HEALTH EDUCATION

advocacy group activities, 438
budgets of Federal agencies, 520–523
Comprehensive Smokeless Tobacco Health Education Act, 478, 481, 490, 511, 512, 518
Comprehensive Smoking Education Act, 478, 479, 481, 490, 512, 517–518
Department of Defense, 426, 521
integration of programs with policy initiatives, 383
national goals, 16–19
National Heart, Lung, and Blood Institute, Smoking Education Program, 424–425
national voluntary health organizations, 394–395, 413–418
prevention of smoking programs, 335–336, 385, 397–398, 401–402, 403–405, 406, 407–408
school-based programs, 388–389, 390, 391, 491–494
Surgeon General's Reports, smoking prevention, 401
teacher training, State requirements, 494, 495
youth programs, cessation of smoking, 392–393

Hispanic Americans

See **ETHNIC GROUPS**

INDIANA

designated smoking areas in hospitals, 586

Inhalation patterns

See **SMOKING CHARACTERISTICS**

INITIATION OF SMOKING

advertising and promotion of tobacco, 501
age, adults vs. adolescents, 296
campaign-related decreases, 666–667
delay, smoking prevention programs, 406
developmental stages models, 385–386
knowledge of health effects, 335–336
lung cancer mortality, men, 45
National Institute for Child Health and Human Development, 399–400
peer pressure, 389–390

- pharmacologic processes and conditioning, 333–335
- prevalence of smoking, 135–136, 137
- price effects, 537–538
- risk personalization, 215
- social influence and life skills training approaches, 390–391
- trends, gender, race, and education, 301

INSURANCE

- auto, 550–551
- biochemical validation of smoking status, life insurance, 545
- coverage of smoking cessation treatment, 552–553, 557
- nonsmoker premium discounts, 543, 544, 546–551
- premium calculations, smoking status, health maintenance organizations, 548
- premium differentials, incentives to stop smoking, 551–552

INVOLUNTARY SMOKING

- biochemical markers, 95–97
- exposure risks, lung cancer, nonsmoking women, 77–78
- Federal workplace policy to limit exposure, 575
- indoor air pollution, lung cancer risk, 53–54
- nonsmokers' rights movement, 442–443
- public annoyance, survey results, 224, 225
- public beliefs about risk, 200, 201
- regulation of environmental tobacco smoke, 613
- sidestream effects, toxic and tumorigenic agents, 88–91
- workplace exposure, restriction rationales, 580–581, 594

LABELING

- Federal Cigarette Labeling and Advertising Act of 1965, 7, 475–476, 477, 482, 518, 519
- Federal Trade Commission requirements, 475–476
- health warnings, 479–482, 484–487, 612
- nicotine polacrilex gum package inserts, 482
- oral contraceptives, 481–482
- oral snuff warning labels, Massachusetts, 612
- Palmer v. Liggett*, 612
- public opinion, 241, 242

LEGISLATION

(See also **TAXATION**)

- Cigarette Labeling and Advertising Act, 441
- Cigarette Safety Act, 614
- Clean Indoor Air Acts, 558, 572, 613
- Comprehensive Smokeless Tobacco Health Education Act, 443, 478, 481, 490, 511, 512, 518, 612
- Comprehensive Smoking Education Act, 398, 437, 443, 478, 479, 481, 490, 512, 517–518
- Consolidated Omnibus Budget Reconciliation Act, 443
- Consumer Product Safety Act, 611
- Controlled Substances Act, 610–611
- Federal Cigarette Contraband Act, 534
- Federal Cigarette Labeling and Advertising Act of 1965, 7, 19, 137, 475–476, 482, 517, 518
- Federal Food, Drug, and Cosmetic Act, 609
- Federal Hazardous Substance Labeling Act, 610, 611
- Food and Drugs Act of 1906, 608–609
- Little Cigar Act, 477, 486, 511
- Minnesota Clean Indoor Air Act, 558
- Occupational Safety and Health Act, 612–613
- Omnibus Budget Reconciliation Act, 528
- Public Health Cigarette Smoking Act, 441, 476, 477, 496, 511, 512, 517, 518, 520
- Public Health Service Act, 613
- Safe Drinking Water and Toxic Substances Enforcement Act, 612
- tobacco access laws, 597–598, 606, 607–608
- Tobacco Products Control Act, Canada, 487
- Toxic Substances Control Act, 611

LITIGATION

- Action on Smoking and Health v. Harris*, 611
- American Public Health Association v. Consumer Product Safety Commission*, 611
- Austin v. Tennessee*, 598
- Cippollone v. Liggett*, 611–612
- Federal Trade Commission v. Brown and Williamson*, 489, 511
- Federal Trade Commission v. Liggett and Myers*, 608–609

Federal Trade Commission v. R.J. Reynolds, 512
Illinois Cigarette Service Co. v. City of Chicago, 598
Mutual Benefit Life Insurance Company v. JMR Electronics Corp., 545–546
Palmer v. Liggett, 612
Parker v. City School Superintendent, 606
U.S.A. v. Liggett, 476
U.S.A. v. R.J. Reynolds, 476

Lobbying

See **ADVOCACY**

LUNG NEOPLASMS

age-specific mortality rates, 143–144
asbestos exposure, smoking and risk, 202
dose–response relationships, 43–46
familial determinants, 52
female mortality, 46–49, 125–126
histologic type, 50–51
inhaled tobacco carcinogens, 93
International Classification of Diseases, 130
male mortality, 44–45
nonsmoker mortality, 141–142
public beliefs, smoking and risk, 185, 186, 188, 189–190, 202
radon and risk, 53–54
vitamins, protective effects, 54

MASS MEDIA

advertising restrictions, 239–240
advertising revenues, 502, 508–510
American Cancer Society, television advertisements, smoking cessation, 414
American Lung Association, series for news broadcasts, 417–418
broadcast ban of tobacco advertisements, 496, 511
Cigarette Advertising Code, 511
coverage of smoking and health related to cigarette advertisers, 509
national voluntary health organizations, television campaigns, 415–416
news media coverage of health risks, 222
public service announcements, 497–500
video news releases, 388

MASSACHUSETTS

availability of tobacco to adolescents, 604–605
Cambridge, smoking restrictions, 577
local smoking ordinances, prevalence, 572
oral snuff, warning labels, 612

public opinion about smoking restrictions, 578
public transit advertising ban, 513

MATERNAL SMOKING

birth defects, dose–response, 72
blacks, 72, 73–74, 275
demographic factors, 275–276
fetal and perinatal mortality, 73
hypoxia, fetal and neonatal effects, 72
infant birthweight, 72–73
infant mortality, 73–74
long-term effects, 75–76
National Institute for Child Health and Development, 400
neurological handicaps, 75–76
public beliefs about smoking effects, 195, 197, 221
socioeconomic status, 276
spontaneous abortion and chromosomal abnormalities, 73

MATHEMATICAL MODELS

attributable risks from cigarette smoking, 153–161
attributable, relative, and absolute risks, hazardous exposure variables, 123–125
avoidable deaths from cancer and coronary heart disease, 131
consumption patterns, changes in smoking-and-health environment, 662–664
dose–response relationships, 44
lung cancer rates among females, 125–126
mortality postponed or avoided, 666–669
smoking prevalence, 270, 651–657
synergy of radon exposure and cigarette smoking, 125

MINNESOTA

Clean Indoor Air Act, 558
excise funding of smoking prevention program, 402
hospital smoking ban, 586
smoking control program, 524, 542
stadium advertising ban, 573

MORTALITY

(See also **MATHEMATICAL MODELS**)

age factors, 41–42, 45
all and specific causes, smokers and ex-smokers, 146–152
attributable risks from smoking, 130–132, 154–156, 206–207
cancer, 47, 48

- cardiovascular and respiratory disease, cancer, 39–40
- diabetes and coronary heart disease, 59
- esophageal neoplasms, 56
- laryngeal neoplasms, 56
- misclassification of cause, International Classification of Diseases, 130
- oral neoplasms, 56
- overall rates, 38–41
- pancreatic neoplasms, 56–57
- postponed deaths, campaign-induced, 666–669
- public beliefs about risks, 206
- relative risk, lung cancer, women, 126
- smoker vs. nonsmoker, 544–545
- smoking-attributable total, 160
- statistical bias, lung cancer risk among women, 129
- stomach neoplasms, 57
- stroke, 61–62, 64
- tax-related changes, 540

MULTIPLE RISK FACTOR INTERVENTION TRIAL (MRFIT)

- advertising by R.J. Reynolds, misrepresentation of study, 512
- mortality and morbidity, smoking habit, 41
- program history, National Heart, Lung, and Blood Institute, 423–424

NATIONAL HEALTH INTERVIEW SURVEYS (NHISs)

- daily cigarette consumption, 292–293, 295
- gender, race, education, 267, 269–270
- initiation of smoking, 297, 301
- methodology and scope, 250–251
- population-weighted mortality data, 122
- prevalence data, self-respondents and proxies, 132–133
- quit ratios, 286, 287
- sampling errors, 129
- smokeless tobacco use, 319–320
- smoking prevalence, 272–274, 298, 299

Native Americans or Alaska Natives
See **ETHNIC GROUPS**

NEOPLASMS

- attributable risks, sex ratio, 1965 and 1985, 153–161
- avoidable risk from smoking, 131–132
- bladder and kidney, smoking dose–response, 56
- public beliefs about smoking risk, 212

NEW YORK

- Clean Indoor Air Act, 572
- commuter rail smoking ban, 573
- compliance with restaurant smoking restrictions, 577
- public opinion about smoking restrictions, 577–578
- workplace smoking policies, 582

NICOTINE

- advertising guidelines, 488–489
- alkaloids in tobacco, 79
- biochemical marker, 95–97
- conditioning and smoking, neurohumoral effects, 343
- deposition, absorption, and metabolism, 93–94
- historic perspective, smoking behavior, 329–330
- metabolism, 94–96
- peptic ulcer, 76
- proposed Federal regulation of cigarette content, 610
- regulation of blood level, 342
- trend for cigarette content, 88

NICOTINE DELIVERY

- alternative products, 615–616
- nicotine aerosols, 616
- nicotine polacrilex gum, 616
- reduced-smoke cigarettes, 617
- smokeless cigarettes, 318–319
- tobacco chewing gum, 616
- tobacco toothpaste, 616

Nicotine polacrilex gum

See **NICOTINE DELIVERY; CESSATION OF SMOKING, METHODS**

NONSMOKERS

- beliefs about personal risks of smoking, 203, 204
- health claims, 549
- insurance premium discounts, 546–548
- lung disease, involuntary smoking, 77–78
- mortality rates, 141–145
- prevalence, 288–289
- workplace smoking restriction, 575, 584, 590, 591

Nonsmokers' rights

See **ADVOCACY**

OCCUPATIONAL DISEASES

- asbestos exposure, public beliefs about smoking risks, 202

workplace exposures, lung cancer risk,
52–53, 128

OCCUPATIONS

blue-collar workers, 272–274
industry type, 585
managers, 585
military personnel, 277–278, 347, 425–
427
white-collar workers, 272

Passive smoking

See **INVOLUNTARY SMOKING**

PEER GROUPS

initiation and maintenance of smoking,
336–338
smokers vs. abstainers, 355
social support, smoking, and cessation,
354–355

PERCEPTION

health risks of smoking, health warnings,
485
positively perceived effects of smoking,
342
social acceptability of smoking, 347

PERSONALITY

extraversion, 336, 345
internal vs. external locus-of-control
dimension, 346
marketing campaigns and personality
characteristics, 339
negative affect smoking, 346
neuroticism, delinquency, and smoking
status, 336
psychosocial factors, smoking habit, 329
relapse rates after smoking cessation, 353

PIPE SMOKING

age-adjusted relative risks, 153
lung cancer mortality, 50
mortality, vs. cigars and cigarettes, 41–42
prevalence among men, 134
socioeconomic and demographic factors,
322, 326–328

PREVENTION OF SMOKING, PROGRAMS

American College of Chest Physicians,
419–420
American Nonsmokers' Rights Founda-
tion, 402
American Pharmaceutical Association,
423
construct validity, 406–407

demographic and historic factors, 408–
409

Department of Defense, 425–427
design and target audiences, trends, 384
dissemination, 403–405
evaluation, 405
Federal Government support, agencies
and reports, 396–401
Federal guides of existing resources, 396
general school health education levels,
389
Great American Smokeout day, 416–417
health professional organizations, 402–
403
historic perspective, 330
long-term followup, 406
mass media, 387–388
National Cancer Institute, 398–399, 421–
423
National Heart, Lung, and Blood In-
stitute, 399, 423–425
National Institute on Drug Abuse, 399
National Interagency Council on Smok-
ing and Health, 395–396
Office of Disease Prevention and Health
Promotion, 400, 425
Office on Smoking and Health, 397–398,
421
psychosocial curricula, 389–392
school health education, 388–389
State, 401–402, 427
voluntary health organizations, 394–395,
407–418
workplace, 425, 432–434
youth, 392–393

POLICIES

advertising imagery and content,
proposals, 515
categorization of tobacco control efforts,
472, 473
educational and behavioral interventions
and initiatives, 383
Fairness Doctrine, 441–442, 496, 660–
661
Health Objectives for the Nation, 16–19,
223–224
history of smoking-and-health research
and regulation, 5–6
national goals for insurance, nonsmoker
premiums and actuarial data, 553–555
restriction of advertising and promotion,
515–516
restriction of smoking, impact on per
capita consumption, 661–662

taxonomy of workplace smoking policies, 581
trends, 409–413
warning labels, Federal Trade Commission requirements, 475–476

PROMOTION

(*See also* **ADVERTISING**)

decreased motivation to stop smoking, 502
encouragement of smoking initiation, 501
encouragement of recidivism, 502
expenditures, 499–500
free distribution of tobacco products, 239, 513, 514, 597, 603–604
nicotine polacrilex gum, 429
proposed restrictions, 515
States prohibiting tobacco sales to minors, 599–602
tobacco consumption, 501–502

Public service announcements

See **ADVERTISING; ADVOCACY; HEALTH EDUCATION; SMOKING CONTROL PROGRAMS**

RECIDIVISM

advertising and promotion of tobacco, 502
body weight and smoking cessation, 354
coping responses, 350
gender differences, 354
prevention strategies, 410, 413
socioeconomic and demographic factors, 353
stress, negative affect, 349
triggers to relapse, 349–350

RESTRICTION OF SMOKING

airplanes, 232, 573–574, 588–589
airports, 574
Clean Indoor Air Act, New York, 572
consumption impact, 591–592, 661–662
Department of Defense, 575
economic impact, 594–595
educational institutions, 561–568, 587–588
Federal Government workplaces, 574–575
fire hazards, 557
health care facilities, 561–568, 585–586, 561–562
industry type and prevalence of smoking policy, 585
local ordinances, 570–572, 577
penalties for noncompliance, 561–568
pharmacies, 587

physician offices and medical organizations, 586
provisions of laws, 560, 568
public places, 232–233, 556–557, 558
public transportation, 561–568, 573, 574
regional variation, 570, 571
restaurants and hotels, 235, 236, 569, 570, 577
State laws, 558–560, 561–569, 569–570, 599–602
target occupational groups, 595
tobacco access laws, 603, 604–606, 607–608
trends in public beliefs, 230–231
vending machines, access, 603–604
workplace policies, 232, 561–568, 600–601, 577, 581–585, 590, 591, 593, 594–595

SEX RATIO

age-specific death rates, 144–145, 146
antismoking campaign effects, 650–657
attributable risks for cancers, coronary and pulmonary diseases, 154–156
initiation of smoking, 296–300
lung cancer mortality, 46
mortality postponed or avoided, 667, 668–669
nonsmoker mortality, 141–142
self-reported daily cigarette consumption, 295
smokeless tobacco use, 320–322
smoking cessation and relapse, 354
smoking continuum, 289–290
smoking prevalence, 132–133, 134–135, 136–137, 138, 269–270, 272, 279, 282–283, 298, 301, 302, 303–305, 307–312, 316

SMOKE STREAMS

mainstream chemical analysis, vapor and particulate phases, 79–85
sidestream effects, toxic and tumorigenic agents, cigarettes, 88–91

SMOKELESS TOBACCO

advertising strategy, graduated use, 507
antismoking pamphlet, American Dental Association, 420
Comprehensive Smokeless Tobacco Health Education Act, 478, 481, 490, 511, 512, 518
disclosure of nicotine content, requirements, 500
Federal excise tax, 528

health warning requirements, 478, 479, 480, 481
nitrosamine formation and oral cancer, 90, 92
snuff-dipping and oral cancer, leukoplakia, 78
State excise taxes, 529

SMOKELESS TOBACCO USE

adolescents, 217, 393
National Cancer Institute prevention programs, 398
prevalence among males, 319–322, 325–326, 657
public beliefs, mouth and throat neoplasms, 202

SMOKING BEHAVIOR

adults, 134–135, 140, 298, 302
advertising effects, 501–502, 506–507
appetitive model, smoking cues, 344
Asian Americans, 275
chronic obstructive pulmonary disease, 68–69
cigarette consumption, 267–268, 293–294, 518–519, 592, 657–662
determinants of smoking, stages, 334
development, maintenance, cessation, 331–332, 334
estimated prevalence in absence of anti-smoking campaign, 651–657
gender, race, education, 269–270, 302–306
heavy vs. light smoking, 181–184, 221
Hispanics, 274
intensity, biochemical markers, 95–97
maintenance, pharmacologic processes and conditioning, 340, 342
men, 269–270
military personnel, 276–278, 575
Native Americans, 274
nicotine dependence, 331, 349
opponent-process theory, aversive withdrawal symptoms, 343–344
oral contraceptive use, 140
personal characteristics, 336, 345–347
pregnant women, 275–276
price elasticity and smoking prevalence, 536–539
public beliefs about duration and health risks, 185, 186–187
public service announcements, 497–500, 514
self-reported status vs. biochemical validation, 265

socioeconomic and demographic factors, 329
State legislative impact, 578–579
State-specific prevalence, 280–281
Third World countries, 19
workplace policies, 584, 589, 591–592

SMOKING CHARACTERISTICS

compensation, 316, 317
inhalation patterns and lung cancer mortality, 45
length of cigarette, market share, 317–318
menthol cigarettes, inhalation, 317
sex ratio, 132–133

SMOKING CONTROL PROGRAMS

hospital prohibition of cigarette sales, 586
knowledge among smokers about health effects, 221
Minnesota, 525, 542
Office on Smoking and Health, 397
Rocky Mountain Tobacco-Free Challenge, 524
tobacco taxes as funding source, 542–543
Utah, excise revenues, 542

SMOKING SURVEYS

(*See also* **ADULT USE OF TOBACCO SURVEYS; CANCER PREVENTION STUDIES; NATIONAL HEALTH INTERVIEW SURVEYS**)

American Medical Association, 247
Behavioral Risk Factor Surveillance System, 247–248, 278–279, 280–281
Chilton Survey, 1979, 248
Collaborative Perinatal Study, 276
Current Population Survey, 248, 279, 282–283, 322
Department of Defense, 276–278, 427
Gallup Surveys, 248–249
High School Seniors Surveys, 296, 302–303, 306
Hispanic Health and Nutrition Examination Survey, 251, 274
Lieberman Research, Inc., 249
methodology, public attitudes on health effects of smoking, 175–177
National Adolescent Student Health Surveys, 250, 296–297, 306–307
National Health and Nutrition Examination Surveys, 251
National Household Surveys on Drug Abuse, 312
National Institute on Drug Abuse High School Seniors Surveys on Drug Use, 251–252

- National Maternal and Infant Health Survey, 275
 - National Natality Surveys, 275
 - National Survey of Family Growth, 276
 - Native Americans and Alaskan natives, 274
 - Roper surveys, 252–253
 - teenagers, 307–309, 310–312
 - U.S. Department of Health, Education, and Welfare Teenage Smoking Surveys, 253
- SNUFF**
- ban on sales, 617–618
 - marketing and labeling, 615
 - warning labels, Massachusetts, 612
- SNUFF-DIPPING**
- adolescents, beliefs about harmfulness, 217, 218
 - adults, 1964 to 1986, 319–322
 - males, 319–322
 - prevalence and proposed ban, 615
- SOCIOECONOMIC STATUS**
- birthweight and maternal smoking, 73
 - blacks vs. whites, smoking prevalence, 269–270
 - cessation and relapse, 353
 - cigar and pipe smoking, 328
 - educational level and occupation, 139
 - personal characteristics and smoking, 347
 - pregnant women, 276
 - smokeless tobacco use among males, 322–323
 - students with blue-collar backgrounds, 408
- SOUTH CAROLINA**
- local smoking restrictions, 572
- STATISTICAL ANALYSIS**
(See also **MATHEMATICAL MODELS; SMOKING SURVEYS**)
- adolescent smoking, weekly vs. daily rates, 307, 312
 - advertising expenditures and tobacco consumption, 504–505
 - age adjustment and relative risk, 127
 - aggregation vs. precision, lung cancer risk among women, 127
 - attributable risk, causation, and mortality, 122–123
 - bias in risk assessments, 128
 - Cancer Prevention Studies, age adjustment of relative risks, 141
 - data errors, exposures and causes of death, 129–130
 - data sources, 264
 - methodology of public opinion surveys, 175–178
 - per capita consumption studies, 657–658
 - risk factor interaction with smoking, 50–51
 - synergy and statistical bias, 128
- STRESS**
- consumption and initiation, smoking habit, 329
 - public beliefs about risks of smoking, 207–210, 212
 - reduction, biological effects of nicotine, 346–347
 - smoking cessation and relapse, 353
- STUDENTS**
- adolescents, personalization of smoking risks, 215
 - beliefs on health effects of smokeless tobacco, 217, 218
 - litigation, school smoking lounges, 606
 - parental awareness of school-based programs, 387
 - program failure to reach dropouts, 407–408
 - school health education curricula, 388–389
 - school smoking restrictions, 587–588
- TAR CONTENT**
- advertising guidelines, 488–489
 - chemical analysis of particulate matter in mainstream smoke, 83–84
 - proposed Federal regulation of cigarettes, 610
 - reductions, 85, 88, 617
 - smokers' gender, age, race, education, 316
- TAXATION**
- ad valorem tax on cigarettes, revenues, 542
 - cigarette price changes, 662
 - evasion of cigarette taxes, cigarette bootlegging, 531–533, 541
 - excise taxes, 264
 - Federal and State tobacco tax increase, effects, 541
 - Federal excise tax, 527–528, 529, 530, 540
 - Indiana, cigarette excise tax, 542
 - licensing requirement for tobacco sales, 604

Minnesota, cigarette excise tax, 402, 525
Nebraska, cigarette excise tax, 542
price elasticity of demand, 533–538
sales tax exemption, 541
smoking-related deaths, effects of tax rates, 540
State and local excise rates and prevalence, 528–532
tax-exempt cigarette sales, impact on States, 533
tobacco tax revenues for State smoking control programs, 542–543
unit tax on cigarettes, 542
Utah, cigarette excise tax, 542

TEXAS

smoke-free hospital rooms, 586
workplace smoking restrictions, 583

TOBACCO ADDITIVES

changes in cigarettes, 139
disclosure requirements, 490
menthol cigarettes, health effects, 317
pesticide traces, 82, 85
reduction of carcinogens, 614
risks and disclosure, 613

TOBACCO INDUSTRY

advertising refuting claims about harmfulness of smoking, 511–512
censorship of smoking and health items, 509–510
Cigarette Advertising Code, 511
code regarding free samples, 597
compliance with health warning legislation, 476, 483
disincentives to advertise, 516
lobbying efforts, 440–441
marketing of low-yield cigarettes, 665
restrictive policies, 595
vending machine sales, 604

TOBACCO SMOKE

physical chemistry, carcinogenic and mutagenic effects, 79–85
tar and neoplasms, 93
toxicity and carcinogenicity, 92–93

UTAH

public transit advertising ban, 513
smoking control program, 542

UTERINE NEOPLASMS

cervical cancer, smoking and other risk factors, 57–58
endometrial and cervical cancers, risk vs. protective factors, 152
endometrial cancer and estrogen levels, 58

VIRGINIA

local smoking restrictions, 572

WOMEN

all-cause and specific mortality, 146–147, 149, 151–152
attributable risk, cancers, cardiovascular and pulmonary diseases, 157–158
attributable risk, lung cancer, 126
cancer mortality risk, 47
cervical and endometrial cancer, 57–58
fertility and smoking, 75
initiation of smoking, 299, 300, 301, 302
lung cancer mortality risk, 46–49, 144
mortality postponed or avoided, smoking cessation or noninitiation, 667, 668–669
National Institute for Child Health and Human Development, cessation of smoking program, 400
oral contraceptive use, 140, 197–199, 481–482
osteoporosis, calcium intake, estrogen, and obesity, 76–77
pregnancy, dangers of smoking, public beliefs, 195, 197–199, 221
pregnancy, demographic factors, smoking prevalence, 275–276
pregnancy, smoking cessation programs, 418, 427
public beliefs about dangers of smoking, 195, 197–199
response to antismoking campaigns, 650–651, 653–657
smoking prevalence, 1965 to 1987, 269–270
stress, smoking cessation and relapse, 353–354
stroke and smoking habit, 62–63